GlobeNewswire by notified

Mendus AB: Mendus presenterar data under SITC 2022 som visar DCOne-plattformens potential att expandera mördarceller (NK) för terapeutiska ändamål

Dela

STIMULERING MED DCONE-CELLER LEDER TILL SELEKTIV OCH STARK >200-FALDIG MEDIANEXPANSION AV NK CELLER MED IMMUNOLOGISKT MINNE

Mendus AB (“Mendus”; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier mot tumöråterfall, tillkännager idag att data som utvärderar vilken potential företagets DCOne-plattform har för att förbättra produktionen av naturliga mördarceller (NK) för terapeutiska ändamål, kommer att presenteras på Society for Immunotherapy of Cancer Annual Meeting 2022, som hålls 8–12 november i Boston, MA, USA (”SITC 2022”). Ett sammandrag av dessa data släpps finns tillgängligt på SITC website.


Naturliga mördarceller (NK) är en typ av immunceller som kan bilda grunden för nya cancerbehandlingar med betydande terapeutisk och kommersiell potential. Därför har strategier och metoder att tillverka NK-celler attraherat betydande finansiering och investeringar från läkemedelsindustrin. Data som presenteras av Mendus på SITC 2022 fokuserar på expansionen av så kallade adaptiva eller minnes-NK-celler med förbättrad funktionalitet, vilken har potential att få överlägsen terapeutisk effekt. Dessa data är resultatet av Mendus oavbrutna forskning, som syftar till att tillämpa allogen dendritcellsbiologi för att utveckla nya immunterapier, och som kan leda till såväl nya kommersiella möjligheter som nya egenutvecklade pipelineprojekt för Mendus.


"De konceptuella data vi kommer att presentera på SITC baseras på en serie experiment som visar hur DCOne-plattformen kan stödja andra cellbaserade immunterapier att prestera bättre och nå ännu fler patienter", säger Alex Karlsson-Parra, forskningschef på Mendus. "Med den över 200-faldiga medianexpansionen av minnes-NK-celler med DCOne-härledda tillgängliga dendritiska celler som denna studie visar, jämfört med den mycket lägre expansion som historiskt rapporterats med andra metoder, skulle vår data kunna lägga grunden för nya immunterapier som är specifikt designade med hjälp av minnes-NK-celler från Mendus och potentiella samarbetspartners."


Posterpresentation

Titel:                Efficient ex-vivo expansion of adaptive NKG2C+/CD57+ NK cells from CMV-positive donors using dendritic cells derived from the acute myeloid cell line DCOne
Nummer på abstract:         386
Länk till abstract:​        https://jitc.bmj.com/content/10/Suppl_2/A407
Tid för presentation:        fredag den 11 nov 2022, från 9.00- 20.30 ET
Rum:         Boston Convention & Exhibition Center, Hall C


Alla posters kommer att vara tillgängliga för deltagare på SITC 2022:s virtuella ePoster-sajt. ePosters kommer också att finnas tillgängliga på mötesappen för SITC och SITCs virtuella mötesplattform för deltagare. Dessutom kommer postern att göras tillgänglig på Mendus hemsida efter presentationen.


FÖR MER INFORMATION VÄNLIGEN KONTAKTA:

Erik Manting
VD
E-post: ir@mendus.com


INVESTOR RELATIONS
Corey Davis
LifeSci Advisors, LLC
Telefon: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com


MEDIAKONTAKT
Mario Brkulj
Valency Communications
Telefon: +49 160 9352 9951
E-post: mbrkulj@valencycomms.eu


OM MENDUS AB (PUBL)

Mendus förändrar behandlingen av cancer genom att fokusera på tumöråterfall och förbättra överlevnaden för cancerpatienter, samtidigt som livskvaliteten bevaras. Vi utnyttjar vår oöverträffade expertis inom allogen dendritcellsbiologi för att utveckla en avancerad klinisk pipeline av nya, lagringsbara, cellbaserade immunterapier som kombinerar klinisk effekt med en god säkerhetsprofil. Mendus är baserat i Sverige och Nederländerna och handlas på Nasdaq Stockholm under tickern IMMU.ST. http://www.mendus.com/

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Power Purchase Agreements signed under South Africa’s REIPPPP Bid Window 58.12.2022 10:49:54 CET | Press release

Oslo / Cape Town, 8 December 2022: Today, Scatec ASA, a leading renewable energy provider in emerging markets, signed power purchase and implementation agreements (Legal Close) for the three solar Grootfontein projects in the Western Cape Province of South Africa, under the Renewable Energy Independent Power Producer Procurement Programme (REIPPPP), alongside the South African government. “We are proud to have reached this milestone in the procurement process - and are excited to continue delivering clean and reliable energy in South Africa. The South African government has shown strong commitment to deliver in challenging times - and today’s achievement is a testament to the hard work and dedication of actors in the country’s renewable energy transition. Scatec continues to drive action and remains the leading solar IPP in the country and continent. We look forward to completing the necessary deliverables in the new year.” says Scatec Executive Vice President for Sub-Saharan Africa, J

Savosolar appoints Kirsi Suopelto as Vice President, Strategy8.12.2022 10:30:00 CET | Press release

Savosolar Plc Company Announcement 8 December 2022 at 10.30 a.m. (CET) Savosolar appoints Kirsi Suopelto as Vice President, Strategy Savosolar has appointed Ms. Kirsi Suopelto, Master of Laws and MBA (born 1976) as Vice President, Strategy of Savosolar Plc and a member of the group's executive management team. Kirsi's tasks include preparation of large investments and financial arrangements as well as M&A projects. Kirsi was elected as the chairperson of the board of Savosolar Plc at the extraordinary general meeting held on November 25, 2022 and at the subsequent organizational meeting of the board. Kirsi has more than 20 years of experience in the financial industry, both in legal and commercial positions. Kirsi has worked for several companies offering financial services in Finland and abroad. She has also been promoting financial industry interests. Kirsi is the chairperson of the board, owner and founder of Hybrid Consulting Oy, which acted as an advisor to VG-Shipping Oy and Meri

Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis8.12.2022 10:12:00 CET | Press release

8 December 2022 Clinigen notesresults from the MIROCALS trial investigating low doseProleukin® (aldesleukin)in patients withamyotrophic lateral sclerosis Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, is pleased to notethe announcement of top-line results from MIROCALS (Modifying Immune Response & OutComes in Amyotrophic Lateral Sclerosis) a phase 2b randomised placebo-controlled trial investigating the efficacy and safety of low dose interleukin-2 (ld IL-2) for controlling neuro-inflammation in newly-diagnosed patients with amyotrophic lateral sclerosis (ALS). The MIROCALS trial, conducted in 220 patients from 17 clinics across the UK and France, in collaboration with eight leading research groups in the UK, France, Italy and Sweden, investigated whether low dose IL-2 can modify aspects of neuro- inflammation, which is believed to play a central role in ALS disease progression. Dr. Gilbert Bensimon presented the top-line results at the International Symposi

Kvika banki hf.: Birkir Jóhannsson new CEO of TM8.12.2022 10:01:44 CET | Press release

Birkir Jóhannsson has been appointed CEO of TM, Kvika banki‘s subsidiary. Birkir will be replacing Sigurður Viðarsson as he takes up the position of deputy CEO at Kvika. Birkir has in past years worked as managing director of core operations and digital solutions at VIS Insurance and has substantial work experience within banking, payment solutions and finance. Birkir has previously been employed at Birti Capital Partners, Valitor, Arion bank and Attorneys atHöfðabakki.. Birkir holds a law degree from the University of Iceland and a master’s degree in corporate finance from Reykjavik University. In addition, Birkir has completed a degree in securities trading and is licensed as a district court attorney. Birkir will be a member of the Kvika group management board. When the changes, that Kvika banki introduced on 5 December, have been implemented the Kvika group management team will consist of Kvika banki’s management board, the CEO of TM, the CEO of Kvika asset management and the CEO o

EV-Joyment, Emotional Promise Motivate EV Adoption Over Environmental Benefits8.12.2022 10:00:58 CET | Press release

Latest Escalent EVForward™ Europe report findings encourage brands to tap into emotional aspirations of BEV ownership to engage with consumers LIVONIA, Mich., Dec. 08, 2022 (GLOBE NEWSWIRE) -- As new-car buyer personas continue to evolve, connecting with consumers’ emotions and personality is more likely to ignite interest in battery electric vehicles (BEVs). This diverges from the long-standing industry narrative that environmental benefits are what drive BEV adoption, creating great opportunity for brands to expand their messaging and embrace new customers with a varying mix of values, lifestyles and attitudes. The environmental and running cost credentials of BEVs are clear, but relatively few car buyers are motivated by such a narrow range of rational criteria. In 2022, 43% of car buyers acknowledge the environmental credentials of BEVs as a benefit, but the same factor only ranks 9th out of 19 in a hierarchy of most important car buying criteria, thus revealing the environment’s l